Kyverna Therapeutics (NASDAQ:KYTX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Kyverna Therapeutics (NASDAQ:KYTX) issued its quarterly earnings results on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09, FiscalAI reports.

Kyverna Therapeutics Stock Down 1.1%

NASDAQ:KYTX traded down $0.11 on Tuesday, reaching $10.23. 612,894 shares of the stock traded hands, compared to its average volume of 861,207. The company’s fifty day simple moving average is $8.89 and its 200 day simple moving average is $8.30. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $619.22 million, a price-to-earnings ratio of -2.80 and a beta of 2.05. Kyverna Therapeutics has a 12 month low of $2.06 and a 12 month high of $13.67.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday, April 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Finally, Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Institutional Trading of Kyverna Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Kyverna Therapeutics during the third quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new stake in shares of Kyverna Therapeutics during the second quarter valued at approximately $43,000. Rhumbline Advisers raised its position in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after buying an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Kyverna Therapeutics during the third quarter valued at approximately $77,000. Finally, Bank of America Corp DE raised its position in shares of Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after buying an additional 6,400 shares during the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.